Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 290

Results For "ED"

9539 News Found

Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future
News | January 20, 2026

Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future

India in the Changing Landscape of Life-Sciences Research & Development


Torrent Pharma secures Rs. 12,500 crore for JB Chemicals takeover
News | January 18, 2026

Torrent Pharma secures Rs. 12,500 crore for JB Chemicals takeover

The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers


JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
News | January 18, 2026

JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr

The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26


Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
News | January 17, 2026

Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation

Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy


HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness
News | January 17, 2026

HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness

The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society


Agno Pharma acquires Actylis Eugene, expanding US API manufacturing footprint
News | January 17, 2026

Agno Pharma acquires Actylis Eugene, expanding US API manufacturing footprint

The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility


Boston Scientific to acquire Penumbra in $14.5 billion deal
News | January 17, 2026

Boston Scientific to acquire Penumbra in $14.5 billion deal

Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion


EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
News | January 17, 2026

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike


GCCL and OPIS forge global clinical trial alliance
Clinical Trials | January 17, 2026

GCCL and OPIS forge global clinical trial alliance

GCCL aims to leverage the partnership to expand strategic relationships with global CROs